Melanoma Cell Expression of CD200 Inhibits Tumor Formation and Lung Metastasis via Inhibition of Myeloid Cell Functions

Hdl Handle:
http://hdl.handle.net/10675.2/777
Title:
Melanoma Cell Expression of CD200 Inhibits Tumor Formation and Lung Metastasis via Inhibition of Myeloid Cell Functions
Authors:
Talebian, Fatemeh; Liu, Jin-Qing; Liu, Zhenzhen; Khattabi, Mazin; He, Yukai ( 0000-0001-7636-5549 ) ; Ganju, Ramesh; Bai, Xue-Feng ( 0000-0001-9476-8376 )
Abstract:
CD200 is a cell surface glycoprotein that functions through engaging CD200 receptor on cells of the myeloid lineage and inhibits their functions. Expression of CD200 has been implicated in a variety of human cancer cells including melanoma cells and has been thought to play a protumor role. To investigate the role of cancer cell expression of CD200 in tumor formation and metastasis, we generated CD200-positive and CD200-negative B16 melanoma cells. Subcutaneous injection of CD200-positive B16 melanoma cells inhibited tumor formation and growth in C57BL/6 mice but not in Rag1-/- C57BL/6 mice. However, i.v. injection of CD200-positive B16 melanoma cells dramatically inhibited tumor foci formation in the lungs of both C57BL/6 and Rag1-/- C57BL6 mice. Flow cytometry analysis revealed higher expression of CD200R in Gr1+ myeloid cells in the lung than in peripheral myeloid cells. Depletion of Gr1+ cells or stimulation of CD200R with an agonistic antibody in vivo dramatically inhibited tumor foci formation in the lungs. In addition, treatment with tumor antigen specific CD4 or CD8 T cells or their combination yielded a survival advantage for CD200 positive tumor bearing mice over mice bearing CD200-negative tumors. Taken together, we have revealed a novel role for CD200-CD200R interaction in inhibiting tumor formation and metastasis. Targeting CD200R may represent a novel approach for cancer immunotherapy.
Citation:
PLoS One. 2012 Feb 3; 7(2):e31442
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10675.2/777
DOI:
10.1371/journal.pone.0031442
PubMed ID:
22319630
PubMed Central ID:
PMC3272017
Type:
Article
ISSN:
1932-6203
Appears in Collections:
Immunotherapy Center Faculty: Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorTalebian, Fatemehen_US
dc.contributor.authorLiu, Jin-Qingen_US
dc.contributor.authorLiu, Zhenzhenen_US
dc.contributor.authorKhattabi, Mazinen_US
dc.contributor.authorHe, Yukaien_US
dc.contributor.authorGanju, Rameshen_US
dc.contributor.authorBai, Xue-Fengen_US
dc.date.accessioned2012-10-26T20:30:42Z-
dc.date.available2012-10-26T20:30:42Z-
dc.date.issued2012-02-3en_US
dc.identifier.citationPLoS One. 2012 Feb 3; 7(2):e31442en_US
dc.identifier.issn1932-6203en_US
dc.identifier.pmid22319630en_US
dc.identifier.doi10.1371/journal.pone.0031442en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/777-
dc.description.abstractCD200 is a cell surface glycoprotein that functions through engaging CD200 receptor on cells of the myeloid lineage and inhibits their functions. Expression of CD200 has been implicated in a variety of human cancer cells including melanoma cells and has been thought to play a protumor role. To investigate the role of cancer cell expression of CD200 in tumor formation and metastasis, we generated CD200-positive and CD200-negative B16 melanoma cells. Subcutaneous injection of CD200-positive B16 melanoma cells inhibited tumor formation and growth in C57BL/6 mice but not in Rag1-/- C57BL/6 mice. However, i.v. injection of CD200-positive B16 melanoma cells dramatically inhibited tumor foci formation in the lungs of both C57BL/6 and Rag1-/- C57BL6 mice. Flow cytometry analysis revealed higher expression of CD200R in Gr1+ myeloid cells in the lung than in peripheral myeloid cells. Depletion of Gr1+ cells or stimulation of CD200R with an agonistic antibody in vivo dramatically inhibited tumor foci formation in the lungs. In addition, treatment with tumor antigen specific CD4 or CD8 T cells or their combination yielded a survival advantage for CD200 positive tumor bearing mice over mice bearing CD200-negative tumors. Taken together, we have revealed a novel role for CD200-CD200R interaction in inhibiting tumor formation and metastasis. Targeting CD200R may represent a novel approach for cancer immunotherapy.en_US
dc.rightsTalebian et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectResearch Articleen_US
dc.subjectBiologyen_US
dc.subjectBiochemistryen_US
dc.subjectGlycobiologyen_US
dc.subjectImmunologyen_US
dc.subjectImmune Cellsen_US
dc.subjectImmunityen_US
dc.subjectImmunologic Subspecialtiesen_US
dc.subjectMedicineen_US
dc.subjectAnatomy and Physiologyen_US
dc.subjectImmune Physiologyen_US
dc.subjectClinical Immunologyen_US
dc.subjectOncologyen_US
dc.subjectCancer Treatmenten_US
dc.titleMelanoma Cell Expression of CD200 Inhibits Tumor Formation and Lung Metastasis via Inhibition of Myeloid Cell Functionsen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3272017en_US
dc.contributor.corporatenameImmunotherapy Center-

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.